Document Detail


Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.
MedLine Citation:
PMID:  8759268     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Ocular cicatricial pemphigoid (OCP) is a severe, potentially sight threatening systemic disease that sometimes requires systemic immunosuppression. This study assessed the clinical outcome of patients with OCP treated with sulphapyridine, a sulphonamide with an anti-inflammatory and immunosuppressive action but few side effects. METHODS: A prospective, single armed, unmasked clinical trial was undertaken at Moorfields Eye Hospital. Twenty consecutive patients with moderate or marked conjunctival inflammation due to OCP were treated with oral sulphapyridine 500 mg twice daily. The degree of ocular inflammation was assessed as nil, mild, moderate, marked, or severe. Success was defined as resolution to mild or less. Ocular limbitis, systemic features of the disease, and side effects of the drug were also monitored. RESULTS: Follow up was a mean of 12.3 (SD 4.0) months and ranged from 7 to 17 months. A successful reduction in inflammation was recorded in 22/39 eyes (56%) and 10/20 patients (50%). This improvement occurred within 1 month in 64% and in all by 2 months. Three patients developed allergy. Other side effects included nausea (n = 3), headache (n = 1), urinary hesitancy (n = 1), and mild lymphocytopenia (n = 1). These were dose dependent. Progression of cicatrisation was observed in 1/22 eyes. Success was less likely if there were systemic features of OCP or ocular limbitis. CONCLUSIONS: Sulphapyridine was clinically effective in 50% of patients with moderate marked inflammation and had few side effects. It is a good alternative to dapsone.
Authors:
M J Elder; J Leonard; J K Dart
Related Documents :
3942418 - The importance of plasma colloid osmotic pressure for interstitial fluid volume and flu...
20874498 - Effectiveness of dorzolamide–timolol (cosopt) in patients who were treatment naive fo...
23163718 - Decreased disability is associated with improved perceived quality of life following sp...
15136318 - Immediate postoperative use of a topical agent to prevent intraocular pressure elevatio...
23660008 - Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up.
18211498 - Isotretinoin: is there any arrhythmic effect?
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  80     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  1996 Jun 
Date Detail:
Created Date:  1996-09-17     Completed Date:  1996-09-17     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  549-52     Citation Subset:  IM    
Affiliation:
Moorfields Eye Hospital, London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Aged, 80 and over
Anti-Inflammatory Agents / therapeutic use*
Conjunctivitis / drug therapy*,  etiology
Female
Humans
Male
Middle Aged
Pemphigoid, Benign Mucous Membrane / complications*
Prospective Studies
Sulfapyridine / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 144-83-2/Sulfapyridine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of epithelial hyperplasia in regression following photorefractive keratectomy.
Next Document:  Bell's phenomenon in newborns and premature babies.